Comparison of single‐cell RNA sequencing data of kidney samples from healthy controls and DKD patients reveals a novel S100A1‐MDM2‐KLF15‐ID1 regulatory axis in DKD pathogenesis and suggests targeting S100A1 might be a potential therapy for proximal tubular injury in DKD.
Abstract
Diabetic kidney disease (DKD) is the leading cause of end‐stage renal disease globally. Tubular injury represents an early pathological hallmark of DKD and a core driver of disease progression. By comparing single‐cell RNA sequencing (scRNA‐seq) data of kidney samples from healthy controls and DKD patients, we found significantly upregulated S100 calcium‐binding protein A1 (S100A1) expression in the proximal tubules of DKD patients, while its role and regulatory mechanism in DKD pathogenesis remain largely unclear. Analysis of renal biopsy specimens from DKD patients showed that S100A1 was markedly upregulated in proximal tubules, and its expression level was significantly correlated with 24‐h proteinuria, serum creatinine, and estimated glomerular filtration rate (eGFR). In vitro, S100A1 promoted tubular injury, inflammatory cytokine release, and fibrotic responses in high glucose‐stimulated human proximal tubular epithelial cells (HK‐2). Mechanistically, S100A1 enhanced the interaction between E3 ubiquitin ligase MDM2 and transcription factor Krüppel‐like factor 15 (KLF15), induced K48‐linked ubiquitination and proteasomal degradation of KLF15, relieved KLF15‐mediated transcriptional repression of inhibitor of DNA binding 1 (ID1), and ultimately aggravated tubular injury. In vivo, proximal tubule‐specific knockdown of S100A1 attenuated renal injury, inflammatory infiltration, and fibrosis in diabetic mice. Our findings reveal a novel S100A1‐MDM2‐KLF15‐ID1 regulatory axis in DKD pathogenesis. Targeting S100A1 might be a potential therapy for proximal tubular injury in DKD.
It is demonstrated that the YOD1-KEAP1 axis mediates oxidative stress injury in RTECs and highlight that targeting YOD1 represents a potential treatment approach for DKD.
Qing-Qing Zhao, Ying Zhao, Shi-Jie Fan et al.· Acta Pharmacologica Sinica· 0 citations
Tubular EZH2 protects against DKD via inhibiting SHC1-driven oxidative stress via epigenetically suppresses the pro-oxidative mediator SHC1, and rescues the exacerbated fibrotic response and oxidative damage triggered by pharmacological EZH2 suppression under high-glucose conditions.
It is demonstrated that impaired pexophagy drives peroxisomal dysfunction and tubular damage in DKD and a critical role of USP30 mediated regulation of pexophagy is revealed and suggested that USP30 may serve as an experimental intervention target to alleviate tubular injury in DKD.
Jia Li, Chaoyang Hua, Guang-Pu Li et al.· Advancement of science· 0 citations
OBJECTIVE
Renal tubular pyroptosis is a key driver of inflammation and fibrosis in diabetic kidney disease (DKD), yet the contribution of the NAIP-NLRC4 inflammasome arm and its upstream transcriptional control have remained undefined. This study investigated whether NAIP causally promotes tubular pyroptosis in DKD and...
Xiaorong Zou, Rui Su, Xue-Yan Liang et al.· Experimental Cell Research· 0 citations
It is suggested that PAQR3 modulates NOX4 protein stability by suppressing its ubiquitination and the PAQR3-STUB1-NOX4 axis may contribute to TIF progression in DKD.